News

Screen Shot 2020-01-21 at 1.55.54 PM.png

While the clinical trials industry has always been a slacker in innovation, we'll soon start seeing automation and artificial intelligence significantly impacting the way biopharmaceutical enterprises run clinical trials, says Moe Alsumidaie.

Daniel_de_Boer.jpg

Therapies aimed at correcting genes that cause diseases are gaining ground in biopharma, some are even specializing in specific mechanisms of action by targeting and modifying RNA through temporary and ongoing treatment. CEO at ProQR Therapeutics, Daniel de Boer, discusses how they are advancing RNA therapies in retinal disorders.